NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Petco Health and Wellness Company, Inc. ("Petco" or the "Company") (NASDAQ: WOOF) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Petco investors who were adversely affected by alleged securities fraud between January 14, 2021 and June 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/petco-laws ...

LAS VEGAS, July 11, 2025 (GLOBE NEWSWIRE) -- Hyperscale Data, Inc. (NYSE American: GPUS), a diversified holding company (“Hyperscale Data” or the “Company”), today announced that it has successfully paid 36 consecutive monthly cash dividends for its 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock (the “Series D Preferred Stock”). Dividends on the Series D Preferred Stock are cumulative and are payable out of amounts legally available therefor at a rate equal to 13.00% per annum per $25.00 of ...

A month has gone by since the last earnings report for Smucker (SJM) . Shares have added about 7.5% in that time frame, outperforming the S&P 500.But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Smucker due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important catalysts.The J.M. Smucker Q4 Earnings T ...

Core Insights - Merus N.V. (MRUS) shares have increased by 29.9% over the past three months, driven by positive interim results from a phase II study of its bispecific antibody, petosemtamab (MCLA-158), in combination with Merck's Keytruda for treating PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) [1][4] Study Results - As of February 27, 2025, 45 patients were treated, with 43 deemed efficacy-evaluable, resulting in a confirmed overall response rate (ORR) of 63%, which included six complete responses and 21 partial responses [2] - The ORR varied with PD-L1 expression levels, showing a 73% ORR in patients with a combined positive score (CPS) greater than 20 and 47% in those with CPS 1–19 [2] - Median progression-free survival was reported at nine months, with an overall survival rate of 79% at 12 months [3] Safety Profile - The safety profile of the combination therapy was manageable, with no significant overlapping toxicities reported with Keytruda; treatment-related adverse events occurred in all patients, with infusion-related reactions observed in 38% [5][6] Future Prospects - The promising data suggests that the petosemtamab combination therapy could become a new standard of care for HNSCC, a cancer type with poor prognosis [6] - Merus is also conducting a registrational phase III study (LiGeR-HN1) for the combination therapy and another study (LiGeR-HN2) for petosemtamab monotherapy [7][8] Market Context - Merck's Keytruda, a leading anti-PD-1 therapy, generated $7.21 billion in sales in Q1 2025, reflecting a 6% year-over-year increase, and continues to expand into new indications and markets [8][10]

Core Viewpoint - Petco Health and Wellness Company, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between January 14, 2021, and June 5, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Petco's pandemic-related growth was not sustainable and that its business model, which focuses on premium pet food, was overstated [2]. - Defendants allegedly downplayed the severity of issues affecting Petco's business and the necessary changes to address these issues, leading to an overstatement of the company's ability to achieve sustainable, profitable growth [2]. - Public statements made by the defendants were claimed to be materially false and misleading throughout the relevant period [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 29, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant compensation for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Group 1: Company Overview - The company primarily produces biodegradable products, including PLA coated paper cups and containers, which accounted for 54.71% of total products in 2024 [1][2] - The main customer sectors include freshly ground coffee, new-style tea drinks, fast food, and supermarkets [2] Group 2: Production Capacity and Operations - The Thailand factory began regular production in April 2025, focusing on orders from the U.S. market and is currently ramping up capacity [2][3] - The company plans to fully promote the production operations of the Thailand base throughout 2025 [3] Group 3: Market Development and Innovation - The company aims to enhance market share through product and technology innovation, targeting long-term partnerships with chain enterprises for stable orders [2][4] - Future development will focus on continuous technological innovation to drive product innovation, aligning with biodegradable product policies [4] Group 4: Competitive Advantages - The company possesses comprehensive processing capabilities, a rich variety of products, and strong R&D in biodegradable dining utensils, providing a competitive edge in the market [4]

Scorpio Tankers (STNG) shares rallied 9.2% in the last trading session to close at $45.55. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 1.2% gain over the past four weeks.Shares of Scorpio Tankers have performed well of late, gaining 11% in the past month. The recent spike in demand for petroleum tankers due to a pause in production from major Middle Eastern exporters has served STNG well.  This shipping c ...

股票代码： 600889 股票简称：南京化纤 编号：2025-039 南京化纤股份有限公司 2025 年半年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 二、上年同期经营业绩和财务情况 （一）利润总额：-7,722.07 万元。归属于上市公司股东的净利润：-6,997.54 万元。归属于上市公司股东的扣除非经常性损益的净利润：-7,112.03 万元。 （二）每股收益：-0.19 元。 三、本期业绩预亏的主要原因 （一）根据《企业会计准则》及公司相关会计政策的相关规定，基于谨慎性 原则，对莱赛尔纤维浆粕、粘胶短纤产成品和粘胶短纤浆粕在 2025 年 6 月 30 日的结存库存进行了减值测试，并相应计提了资产减值，增加了经营亏损。 （二）公司全资子公司南京金羚生物基纤维有限公司部分在建工程于 2024 年 9 月转固导致 2025 年上半年固定资产折旧与上年同期相比大幅增加，扩大了 经营亏损。 （三）公司控股子公司上海越科新材料股份有限公司 2025 年上半年 PET 发 泡产品销量大幅增加， ...

IEA月报：6月沙特石油产量飙升，远高于OPEC+配额。 ...

交易咨询业务资格：证监许可【2012】1091号 PTA&MEG早报-2025年7月11日 大越期货投资咨询部 金泽彬 投资咨询资格证号：Z0015557 联系方式：0575-85226759 重要提示：本报告非期货交易咨询业务项下服务，其中的观点和信息仅作参考之用，不构成对任何人的投资建议。 我司不会因为关注、收到或阅读本报告内容而视相关人员为客户；市场有风险，投资需谨慎。 CONTENTS 目 录 1 前日回顾 2 每日提示 3 4 今日关注 基本面数据 5 PTA 每日观点 PTA： 1、基本面：昨日PTA期货跟随成本端震荡收涨，现货市场商谈氛围一般，日内伴随个别主流供应商出货及聚酯大厂减产消息， 现货基差走弱，贸易商商谈为主，零星聚酯工厂递盘，7月货在09+0~20有成交，个别略低，价格商谈区间在4720~4750附近。 今日主流现货基差在09+7。中性 2、基差：现货4735，09合约基差-7，盘面升水 中性 3、库存：PTA工厂库存3.95天，环比减少0.14天 偏多 4、盘面：20日均线向下，收盘价收于20日均线之下 偏空 5、主力持仓：净空 空减 偏空 6、预期：从基本面来看，7月检修不多，另 ...